A bullet-point review of the week that was the third of July 2013.
A summary of commercialisation news from the 22 July to the 28th.
Cardiff tech cluster set to expand
Cardiff’s tech cluster adds life science firm ReNeuron to the area after a £13.8m investment to relocate to the Welsh capital from the Wales Life Science Fund.
Michigan cancer-fighting biotech spin-out lands $82m in IPO.
Medtech spin-out Saluda Medical receives $5m backing from the New South Wales Government.
Life science firm Illumina acquires Duke spin-out Advanced Liquid Logic, a provider of liquid handling solutions, for $94m.
RealVNC set to join Cambridge’s $1bn club
A Cambridge software spin-out, RealVNC, is tipped to become the next $1bn Cambridge company by the Royal Academy of Engineering.
Un-Dynamic $46m IPO for Cellular
Wisconsin-Madison spin-out Cellular Dynamics raises $46m in an IPO.
Venture-backed online course provider Udacity wobbles as more than 50% of students at San Jose State University using its courses fails their courses.
The University of Maryland receives $3.8m for 17 projects to bring its tech closer to market.
Uppsala to commercialise the impossible
An “impossible” material with a record-breaking surface area is to be commercialised by Uppsala University.
Imperial spin-out Ceres Power signs commercial and technical partnership with boiler manufactuer KD Navien.
TB Biosciences, a life sciences firm commercialising tuberculosis detection kits, receives $1.5m in series A funding.
Irish tech transfer finds director
The Irish Universities Association announces the appointment of director of tech transfer.
Northeastern to collaborate with Rogers
Northeastern University announces deal with speciality materials company Rogers to jointly establish innovation centre.
Michigan State University spin-out BioPhotonics raises $2m in venture backing from angels.
Michigan’s entrepreneurial direction
The University of Michigan has named a new executive director for its Centre for Entrepreneurship.
Professor Theodore Moustakas is named Boston University’s leading innovator.
B-To-V Partners, a Switzerland-based angel network, and UK-based peer Rosetta Capital invests €30m in 13 out of 25 portfolio companies of Karolinska Development, an independent investment company backing the Sweden-based Karolinska Institute medical university.
